Free tool
FAERS Monitor: Accrufer
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212320 or its brand name (Accrufer, Ferric Maltol). Reports on generic versions are filed under their own applications.
Reports
1,060
Serious
214
20% of reports
Hospitalization
87
Death reported
42
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- constipation160
- inappropriate schedule of product administration108
- abdominal discomfort104
- diarrhoea103
- nausea99
- abdominal pain upper75
- maternal exposure during pregnancy71
- treatment noncompliance61
- drug ineffective51
- off label use42
- death39
- vomiting34
- dizziness27
- faeces discoloured23
- fatigue23
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 7 |
| 2022 | 35 |
| 2023 | 93 |
| 2024 | 272 |
| 2025 | 576 |
| 2026 | 69 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,099 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| treatment noncomplianceSignal | 61 | 22.1 | 17.4 | 1,213 |
| faeces discolouredSignal | 23 | 21.1 | 14.1 | 420 |
| maternal exposure during pregnancySignal | 71 | 15.8 | 12.6 | 974 |
| constipationSignal | 160 | 14.6 | 12.6 | 2,028 |
| abdominal discomfortSignal | 104 | 12.3 | 10.3 | 1,077 |
| inappropriate schedule of product administrationSignal | 108 | 11.9 | 9.9 | 1,076 |
| abdominal pain upperSignal | 75 | 7.2 | 5.8 | 400 |
| diarrhoeaSignal | 103 | 3.2 | 2.6 | 155 |
| nauseaSignal | 99 | 2.5 | 2.1 | 90 |
| vomiting | 34 | 1.4 | 1.0 | 4 |
| dizziness | 27 | 1.1 | 0.7 | 0 |
| off label use | 42 | 1.0 | 0.7 | 0 |
| death | 39 | 0.9 | 0.7 | 0 |
| drug ineffective | 51 | 0.8 | 0.6 | 4 |
| fatigue | 23 | 0.6 | 0.4 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.